

INDEX

A

Autophagy
 LC3 152, 153, 158–161

B

Bioactive lipids
 eicosanoids 17, 18, 27, 31–33
 Blood-Like Medium (BLM) 190–194, 196–200,
 202–204, 208, 210–213

Bone

bone turnover biomarkers 251–261
 human bone tissue culture 251–261
 secretome vi

C

Cancer vi, 39, 53–64, 68, 109, 110, 121, 137,
 151, 154, 159, 162, 163, 217, 218, 246, 252,
 255, 257, 260

Cell death pathways

apoptosis 163–166
 necroptosis 163, 165
 necrosis 163, 165, 166

Cells

bone cells 251
 cancer cells 53–64, 67, 110, 151, 152,
 154, 159, 163, 252
 endothelial cells (ECs) v, 121–135, 236, 246
 human cells 85, 90, 91, 95, 110, 191,
 193, 228, 252
 macrophages 174, 176, 242, 246
 mouse cells 177, 192, 194, 229, 230
 T cells 187, 189, 202, 209, 210, 212

Compartmentalization 137

Credentialing 2, 3, 8, 9, 11–13

¹³C tracer analysis

¹³C glucose infusions 68, 69
 pathway activity 67

Custom media formulation 197, 199, 210, 213

D

Deuterium tracing 84, 85

E

Endothelium

endothelial cells (ECs) 122
 Extracellular acidification 148, 174

F

Flux

ATP synthesis 97–107
 compartment resolved fluxes v
 extracellular flux analyzer
 (i.e. seahorse XF analyzer) 140, 174–176, 180
 fatty acid oxidation (i.e. β -oxidation) 97
 flux inhibition assay 109–119
 glucose oxidation 123, 125, 127, 130, 132
 glutamine oxidation 123, 127–135
 glycolysis 122, 123, 125, 128,
 130–134, 174
 glycolytic flux 123, 125, 134
 metabolic flux v, 39, 109–119, 137–149,
 174, 189, 190, 207, 208
 mitochondrial flux 121–135
 pulse-stop-flux 109

H

Heat maps

correlation 280, 283, 285, 286,
 288, 289
 dendrogram 281–283, 289
 hierarchical clustering 280–289
 linkage method 288–290

I

Imaging

fluorescent microscopy 158, 269
 fluorescent proteins 229, 236
 multi-photon laser scanning microscopy 227, 229
 multicolor 3D images 227

Immunometabolism 174, 187

In vitro cell culture

adherent cells (i.e. 2D culture) v, 37, 87, 90
 spheroids (i.e. 3D culture) v, 54

L

Lipid metabolism
 bioactive lipids27, 33
 de novo lipogenesis (DNL) 84, 85, 94
 lipidomics..... 18

M

Macrophages
 polarization vi, 173–186

Mass spectrometry
 gas chromatography-mass spectrometry
 (GC-MS)..... 39, 54, 56–57, 59, 61,
 62, 64, 72, 77, 78, 81, 86, 91, 93, 138, 140, 141,
 143, 146
 liquid chromatography-mass spectrometry
 (LC-MS)18–20, 22, 25–27, 29, 39, 41,
 45–47, 50, 51, 54–57, 61, 62, 71, 73, 78, 79, 81,
 97, 146

Metabolic signaling v, 175

Metabolism
 amino acid metabolism v, 38, 39, 45–47, 51,
 71, 77, 86, 151, 163, 189, 191, 192, 208
 cancer metabolism..... 39, 67, 68, 109, 163
 glutamine metabolism 47, 86, 122, 129,
 174, 175, 182, 199
 nutrient metabolism..... v, 37–52

Metabolomics
 amino acid chemical derivatization 37
 carbon-13 (¹³C) 6, 53–64, 84, 109, 117
 deuterium 83
 heavy isotope labeling 109–119
 metabolite extraction38, 54
 metabolite profiling..... 1
 quenching.....38, 54
 stable isotope v, 39, 53, 67
 untargeted metabolomics 1–14

Microscopyvi, 152, 158, 159, 166, 168,
 169, 178, 227, 269, 273

Mitochondria
 bioenergetics..... 97, 175
 mitochondrial metabolism 137
 mitochondrial morphology263, 264, 268, 269

oxidative phosphorylation (OXPHOS)97, 98,
 101, 102

Mouse surgery
¹³C glucose infusions 67
 lipectomy 247
 patient-derived tumor xenografts 217, 224
 Multiplex immunoassay 251–261

N

Nutrient environment67, 121, 152, 174,
 188, 189

O

Organelle organization
 lysosome positioning264, 266, 269, 270
 micropatterning.....264, 266
 organelle positioning 264, 266, 267
 Oxygen consumption 138, 139, 174

P

Pathway activity v, 53, 67, 109
 Pathway inhibition 109–119
 Patient-derived xenografts (PDX)..... vi, 68, 217

R

Radioactive tracersv, 121–135

T

T cells
 activation 189, 192, 194, 201, 202, 212
 CD8+ T-cells 189, 192, 194, 200–203,
 208, 211–213
 effector differentiation189, 194, 202, 203
 T lymphocytes (i.e. T cells) 253

V

Visceral adipose tissue
 high-fat diet 246, 249
 lipectomy 246, 247
 obesity 245, 246